CNBC.com found the best performing investors you probably have never heard of, but are beating the market these days. Here are their top picks.
Actavis President & CEO Brent Saunders explains the new corporate name, and the strong earnings beat. "We keep surprising people," says Saunders.
It was man versus machine when Bill Ackman interviewed Ray Dalio in New York.
Allergan chief David Pyott tells CNBC that dealing with "raiders" like Bill Ackman and Valeant Pharmaceuticals was a full-time job.
David Pyott, Allergan chairman & CEO, discusses the company's historic quarter, Bill Ackman's failed attempt to take over the company and the decision to subdivide the management team.
M&A experts forecast there will be more major pharma deals in 2015 — but the U.K. won’t be a focus and the deals won’t be done for tax reasons.
Some of the names on the move ahead of the open.
Bill Ackman appears set to take it easy for a few months after knockout performance in 2014.
The drugmaker has engaged in $100 billion of M&A in the last year, but CEO Brent Saunders told CNBC it is committed to innovation.
Activist shareholders in 2014 helped the mergers and acquisitions landscape return to the pre-crisis days of 2007 – and they'll continue to make news.
Activist investor famous for his high-profile battle with Herbalife claims short was 'most philanthropic investment I have ever made.'
Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.
Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.
Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.
"Mad Money" host Jim Cramer on the players that could keep tearing it up in 2015.
Jim Cramer reviews the Top 10 stocks of the S&P 500 for 2014. Will they be winners again this year?
Bill Ackman renewed his attack on Herbalife during a CNBC interview Wednesday, likening the nutrition and weight management company to Bernie Madoff.
On a down day in the market, Jim Cramer thinks this is the perfect time to review the silly preconceptions of 2014.
Critics love to hate hedge fund fees and performance, but the industry is poised to grow even more in 2015.
CNBC's Kate Kelly reveals what investors can expect from hedge funds and activists in 2015.